The Psychedelic Therapeutics and Drug Development Conference

Memo

The Psychedelic Therapeutics and Drug Development Conference has been organized to bring together the world's leading researchers and leaders in academia and industry to discuss the challenges and opportunities facing those engaged in the research and development of psychedelics for various health conditions with considerable unmet need. This event will highlight the progress being made towards regulatory approval of a variety of psychedelics with the potential to treat various conditions, including inflammatory/autoimmune disorders, brain injury, pain, PTSD, anxiety, ADHD, headaches, depression, and opioid use disorder. Conference Themes: Clinical trial designRisk Evaluation and Mitigation Strategy (REMS)Abuse potentialPractical use/indications/DEA licensure and policy considerationsTargets for novel drug developmentDosage (micro/low/high)Second generation psychedelic drug designFDA regulatory guidanceToxicology studies and considerations URLs:Tickets: https://go.evvnt.com/725049-0?pid=5569 Website: https://go.evvnt.com/725049-3?pid=5569  Date and Time: On Tuesday May 04, 2021 at 9:30 am (ends Wednesday May 05, 2021 at 3:00 pm) Prices:Industry: USD 450.00,Academic: USD 250.00,Non-Profit: USD 250.00,Government: USD 250.00,Student: USD 150.00 Speakers: Bryan Roth, University of North Carolina School of Medicine, Charles Nichols, LSU Health Sciences Center, Frederick Barrett, Johns Hopkins School of Medicine, Alan Kozikowski, Bright Minds, Javier Gonzalez-Maeso, Virginia Commonwealth University School of Medicine